FDA to review Novavax’s Covid-19 vaccine in June

eAwaz Medicine

Los Angeles – Food and Drug Administration has announced that an advisory committee is set to meet June 7 to examine the benefits and risks of Novavax Inc’s experimental Covid-19 vaccine. Novavax’s protein-based vaccine has been authorized in several countries, including by the UK and the European Commission, but is still being reviewed by the FDA. The company’s stock has tumbled 65.6% this year, while the broader S&P 500 SPX, -3.63% is down 10.0%.